Newsbenzinga
Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
· Published
Article summary
Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.
An excerpt from the original article.
Comments —
Loading comments…